Pricing and Reimbursement Application Tracker
Login
Search
tislelizumab (Tevimbra®)
Application Details
HSE Application ID
HSE100093
HTA Number
HTA Link
Drug
tislelizumab
Brand
Tevimbra®
Applicant
BeOne Medicines Ireland Limited
Indication Applied For
Tislelizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) who have: • locally advanced non-small cell lung cancer (NSCLC) and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic non-small cell lung cancer (NSCLC).
Application Date
17/03/2026
Marketing Authorisation Date
08/07/2024
Application Status
Pricing and Reimbursement Application Complete
17/03/2026
Rapid Review Commissioned
11/03/2026
New Search
Status
Pricing and Reimbursement Application Complete
Rapid Review Commissioned
Rapid Review Completed
Applicant Meeting Held with CPU
Awaiting Proposal from Applicant
Proposal from Applicant Under Review
Full Health Technology Assessment Commissioned by HSE
NCPE Assessment Completed
HSE Drugs Group Review Pending
Reviewed by HSE Drugs Group
HSE Rare Disease Technology Review Committee - Review Requested
HSE Rare Disease Technology Review Committee - Review Received
Further Information Requested by HSE Drugs Group
Reviewed by HSE Senior Leadership Team
Managed Access Protocol (MAP) Commissioned
Proposed HSE Decision Issued to Applicant
Applicant Representations Received
HSE Decision Issued to Applicant
Application On Hold at the Request of Applicant
Application Withdrawn at the Request of Applicant
Application on Hold as Agreed by HSE and Applicant
HSE Approval Letter Issued to Applicant
Full Health Technology Assessment Submitted to NCPE
Delete Application
×
Are you sure you want to delete this Application?
Once it's deleted it cannot be retrieved.
Remove Status and Date
×
Are you sure you want to delete this?